(Q40359103)

19 September 2017

Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits (English)

1 reference

Ana Maria Gonzalez-Angulo

19 September 2017

metastatic breast cancer

1 reference

1 reference

2

object named as

A M Gonzalez-Angulo

1 reference

19 September 2017

C H Yang

1

1 reference

19 September 2017

J M Reuben

3

1 reference

19 September 2017

D J Booser

4

1 reference

19 September 2017

L Pusztai

5

1 reference

19 September 2017

S Krishnamurthy

6

1 reference

19 September 2017

D Esseltine

7

1 reference

19 September 2017

J Stec

8

1 reference

19 September 2017

K R Broglio

9

1 reference

19 September 2017

R Islam

10

1 reference

19 September 2017

G N Hortobagyi

11

1 reference

19 September 2017

M Cristofanilli

12

1 reference

19 September 2017

10 January 2006

1 reference

19 September 2017

1 reference

19 September 2017

17

1 reference

19 September 2017

5

1 reference

19 September 2017

813-817

1 reference

19 September 2017

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ131

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ131

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ131

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ131

Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ131

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ131

Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ131

Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ131

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ131

Proteasome inhibition in cancer: development of PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ131

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ131

Images in clinical Medicine. Bortezomib-induced skin lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ131

Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ131

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ131

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDJ131

1 reference

19 September 2017

1 reference